ReviewInternational journal of nanomedicine2007
Nanoparticulate carriers for the treatment of coronary restenosis.
Review in International journal of nanomedicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 99 citations in OpenAlex.
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention.Molecules (Basel, Switzerland) · 2022Article
- Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy.APL bioengineering · 2021Review
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Nanoparticle eluting-angioplasty balloons to treat cardiovascular diseases.International journal of pharmaceutics · 2019Article
- Application of Light Scattering Techniques to Nanoparticle Characterization and Development.Frontiers in chemistry · 2018Review
- Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases.International journal of nanomedicine · 2018Review
- Nanotechnology in diagnosis and treatment of coronary artery disease.Nanomedicine (London, England) · 2016Review
- Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury.Experimental and therapeutic medicine · 2015Article
- [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction.Biomaterials · 2015Article
- Article
- Advances in nanotechnology for the management of coronary artery disease.Trends in cardiovascular medicine · 2013Review
- Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.Cellular and molecular life sciences : CMLS · 2012Review
- Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin.International journal of nanomedicine · 2012Article
- In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Restenosis after PCI. Part 2: prevention and therapy.Nature reviews. Cardiology · 2011Review
- Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement.PloS one · 2010Article
- Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.Trends in pharmacological sciences · 2010Review
- Gold nanoparticles: From nanomedicine to nanosensing.Nanotechnology, science and applications · 2008Review
- Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles.Pharmaceutical research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or a drug-eluting stent. Despite the high usage of commercially-available drug-eluting stents in the cardiac field, there are a number of limitations. This review will present the background ofrestenosis, go briefly into the molecular and cellular mechanisms of restenosis, the use of mechanical stents in coronary restenosis, and will provide an overview of the drugs and genes tested to treat restenosis. The primary focus of this article is to present a comprehensive overview on the use of nanoparticulate delivery systems in the treatment of restenosis both in-vitro and in-vivo. Nanocarriers have been tested in a variety of animal models and in human clinical trials with favorable results. Polymer-based nanoparticles, liposomes, and micelles will be discussed, in addition to the findings presented in the field of cardiovascular drug targeting. Nanocarrier-based delivery presents a viable alternative to the current stent based therapies.
Indexed as
Identifiers
17722543PMC2673979W2133944580What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.